Showing results (111-120 of 147) with videos related to
Sort By:
Pageof 15
Lancet (London, England)|May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.The Lancet. Oncology|April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trialMahrukh M Syeda, Georgina V Long, James Garrett, et al.Pigment Cell & Melanoma Research|October 7, 2019
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanomaRobert Mason, Helen C Dearden, Bella Nguyen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2026
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)Gregory M Cote, Mason Aberoumand, Edwin Choy, et al.Journal for Immunotherapy of Cancer|August 3, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, et al.Nature Medicine|October 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trialTimothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, et al.Journal of Cancer Research and Clinical Oncology|August 22, 2023
Detection of metastases using circulating tumour DNA in uveal melanomaAaron B Beasley, Daniël P de Bruyn, Leslie Calapre, et al.Cancer Immunology, Immunotherapy : CII|July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaAntoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.NPJ Precision Oncology|September 9, 2024
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutationSubotheni Thavaneswaran, Frank Lin, John P Grady, et al.Pageof 15